Get the Stockscreener App
1.61
1.23%
-0.02
Actinium Pharmaceuticals Inc stock is traded at $1.61, with a volume of 151.20K.
It is down -1.23% in the last 24 hours and up +19.26% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.63
Open:
$1.63
24h Volume:
151.20K
Relative Volume:
0.46
Market Cap:
$50.23M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-0.8798
EPS:
-1.83
Net Cash Flow:
$-47.49M
1W Performance:
-10.06%
1M Performance:
+19.26%
6M Performance:
+38.79%
1Y Performance:
-75.68%
1-Day Range:
$1.57
$1.68
1-Week Range:
$1.54
$1.79
52-Week Range:
$1.06
$6.51
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.61 | 50.85M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
What are analysts’ price targets for Actinium Pharmaceuticals Inc. in the next 12 monthsBeginner Investor Review Backed By Experts - jammulinksnews.com
Actinium Pharmaceuticals shares rise 5.73% intraday after presenting positive data for ATNM-400 in prostate cancer treatment. - AInvest
New Prostate Cancer Drug ATNM-400 Shows 40% Complete Cure Rate vs Pluvicto | ATNM Stock News - Stock Titan
Will Actinium Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsFree Risk Managed Intraday Trade Alerts - Newser
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficac - Ariva
Actinium Pharmaceuticals Inc. recovery potential after sell offWatchlist Generator for Smart Money Signals - Newser
Published on: 2025-07-31 05:11:29 - metal.it
What’s next for Actinium Pharmaceuticals Inc. stock priceTrade Scanner With Buy Zone Alerts Flagged - metal.it
Why Actinium Pharmaceuticals Inc. stock attracts strong analyst attentionEarly Entry Tips With Low Risk Zone Shared - metal.it
How to interpret RSI for Actinium Pharmaceuticals Inc. stockChart Based Entry Tool for ROI Traders - Newser
Can machine learning forecast Actinium Pharmaceuticals Inc. recoveryFree Smart Money Tracking Signal Generator - Newser
Can Actinium Pharmaceuticals Inc. Rally Enough to Break EvenTriple Return Setup With Risk Control Explained - metal.it
Published on: 2025-07-29 14:09:30 - metal.it
Is Actinium Pharmaceuticals Inc. showing signs of accumulationMarket Downturn Defense Strategy Analysis - Newser
Visual analytics tools that track Actinium Pharmaceuticals Inc. performanceLow Risk Stock Trade Opportunity Analysis - Newser
Is Actinium Pharmaceuticals Inc. stock a growth or value playFree Smart Trend Trading with Weekly Signals - Newser
Does Actinium Pharmaceuticals Inc. fit your quant trading modelDaily Market Momentum and Pressure Analysis - Newser
What are the latest earnings results for Actinium Pharmaceuticals Inc.Daily Trading Forecasts From AI Tools - jammulinksnews.com
What institutional flow reveals about Actinium Pharmaceuticals Inc.Long Term Stock Growth Plan Suggestions - Newser
Key External Factors That Drive Actinium Pharmaceuticals Inc. Stock Price MovementsTrading Volume Spike and Reversal Analysis - Newser
Actinium Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowHigh Probability Trade Outcome Prediction - Newser
Using Bollinger Bands to evaluate Actinium Pharmaceuticals Inc. Quarterly Investment Outlook and Key Summary - Newser
Why is Actinium Pharmaceuticals Inc. stock attracting strong analyst attentionSuperior risk-adjusted returns - jammulinksnews.com
What is the risk reward ratio of investing in Actinium Pharmaceuticals Inc. stockMaximize returns with disciplined trading - jammulinksnews.com
How strong is Actinium Pharmaceuticals Inc. company’s balance sheetDiscover investment plans that deliver results - jammulinksnews.com
What is Actinium Pharmaceuticals Inc. company’s growth strategyBuild wealth with reliable stock picks - jammulinksnews.com
Is it the right time to buy Actinium Pharmaceuticals Inc. stockUnprecedented profits - jammulinksnews.com
When is Actinium Pharmaceuticals Inc. stock expected to show significant growthGrow your wealth with proven stock picks - jammulinksnews.com
What institutional investors are buying Actinium Pharmaceuticals Inc. stockUnlock powerful insights from market experts - jammulinksnews.com
Actinium Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveFree Access to Community - Newser
Is Actinium Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025Free Stock Market Real-Time Monitoring - Newser
Actinium Pharmaceuticals Inc. Stock Performance After Earnings: Historical InsightsStrong Buy Recommendations - Newser
What institutions are buying Actinium Pharmaceuticals Inc. stock nowSuperior investment outcomes - jammulinksnews.com
What drives Actinium Pharmaceuticals Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Is Actinium Pharmaceuticals Inc. a good long term investmentRapid growth opportunities - Autocar Professional
What analysts say about Actinium Pharmaceuticals Inc. stockHigh-yield growth strategies - PrintWeekIndia
What analysts say about Actinium Pharmaceuticals Inc. stock outlookUnbelievable profit margins - jammulinksnews.com
Actinium Pharmaceuticals Inc. Stock Analysis and ForecastHigh-performance investment picks - jammulinksnews.com
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):